Log in

Beyondspring Stock Forecast, Price & News

+0.14 (+0.93 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $15.23
50-Day Range
MA: $12.20
52-Week Range
Now: $15.23
Volume193,644 shs
Average Volume101,025 shs
Market Capitalization$458.54 million
P/E RatioN/A
Dividend YieldN/A
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Read More
Beyondspring logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BYSI



Sales & Book Value

Annual SalesN/A
Book Value$1.12 per share


Net Income$-38,080,000.00


Market Cap$458.54 million
Next Earnings Date12/16/2020 (Estimated)
OptionableNot Optionable
+0.14 (+0.93 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Beyondspring (NASDAQ:BYSI) Frequently Asked Questions

How has Beyondspring's stock been impacted by COVID-19?

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BYSI shares have increased by 34.2% and is now trading at $15.23.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Beyondspring?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beyondspring

When is Beyondspring's next earnings date?

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, December 16th 2020.
View our earnings forecast for Beyondspring

How were Beyondspring's earnings last quarter?

Beyondspring Inc (NASDAQ:BYSI) issued its earnings results on Thursday, September, 3rd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.11.
View Beyondspring's earnings history

What price target have analysts set for BYSI?

4 analysts have issued 1 year target prices for Beyondspring's stock. Their forecasts range from $25.00 to $46.00. On average, they anticipate Beyondspring's stock price to reach $35.00 in the next year. This suggests a possible upside of 129.8% from the stock's current price.
View analysts' price targets for Beyondspring

Who are some of Beyondspring's key competitors?

What other stocks do shareholders of Beyondspring own?

Who are Beyondspring's key executives?

Beyondspring's management team includes the following people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 48)
  • Mr. Dongheng Liu, Chief Financial Officer (Age 37)
  • Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 58)
  • Dr. Ramon W. Mohanlal, Exec. VP of R&D and Chief Medical Officer (Age 61)
  • Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 75)

When did Beyondspring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is Beyondspring's stock symbol?

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Who are Beyondspring's major shareholders?

Beyondspring's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jefferies Group LLC (0.51%), Monashee Investment Management LLC (0.33%), Marshall Wace LLP (0.30%), Goldman Sachs Group Inc. (0.27%), Russell Investments Group Ltd. (0.17%) and Marshall Wace North America L.P. (0.14%).

Which major investors are selling Beyondspring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and UBS Group AG.

Which major investors are buying Beyondspring stock?

BYSI stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Monashee Investment Management LLC, Marshall Wace LLP, Marshall Wace North America L.P., Nuveen Asset Management LLC, California Public Employees Retirement System, Blair William & Co. IL, and Russell Investments Group Ltd..

How do I buy shares of Beyondspring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beyondspring's stock price today?

One share of BYSI stock can currently be purchased for approximately $15.23.

How big of a company is Beyondspring?

Beyondspring has a market capitalization of $458.54 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

What is Beyondspring's official website?

The official website for Beyondspring is www.beyondspringpharma.com.

How can I contact Beyondspring?

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.